EXECUTIVE INTERVIEWS

Guiding Bayer’s Global Innovation Engines To New Heights

A little over a year ago, Kemal Malik received some really good news — he’d been promoted. The former head of global development and chief medical officer in the pharmaceuticals division at Bayer AG had been appointed to the company’s five-member board of management. If you have ever received similar news, you probably recall the initial feeling of euphoria.

More From Executive Interviews

THE CURRENT ISSUE

  • Innovation In Clinical Trials: What Can We Expect In 2015 And Beyond?
    Innovation In Clinical Trials: What Can We Expect In 2015 And Beyond?

    Innovation is a critical topic in the pharmaceutical industry. It is what will help the industry keep on top of quality issues, develop new products, speed needed medicines to patients, and bring down the cost of the entire process. However, identifying where it can best happen and then making the vision a reality is also one of the toughest challenges that sponsors face.

  • Quality Is Never An Issue, Until It Becomes An Issue
    Quality Is Never An Issue, Until It Becomes An Issue

    I don’t spend a lot of time thinking about quality. I doubt that most consumers do, even when purchasing pharmaceutical products. I have leg pain for which I take Ibuprofen almost daily. I also have a prescription medicine I take once a day. Even for these products, which could easily affect my health and well-being, I do not stop to consider the manufacturer, country of origin, or most importantly, whether it was manufactured by a company with a focus on quality. Like most consumers, I just assume it [quality] is there.

  • How Leaders Can Promote Continuous Learning In Today’s Organizations
    How Leaders Can Promote Continuous Learning In Today’s Organizations

    When it comes to effectively leading organizations in today’s 24/7 global economy, it’s clear that the days of command-and-control leadership are well behind us.

  • Deal Flow Prompts Companies To Understand New Revenue Recognition Standard
    Deal Flow Prompts Companies To Understand New Revenue Recognition Standard

    Whether you’re ready or not, significant accounting changes are coming, and they aren’t just a problem for your auditor. For life sciences companies considering a merger, acquisition, or strategic partnership in the near future, an understanding of the new standard for revenue recognition (i.e., what month earnings are reported on the financial statement) and its potential impact on deal structures will be critical.

  • Advice From A Serial Pharmaceutical Entrepreneur
    Advice From A Serial Pharmaceutical Entrepreneur

    Twenty-two years after graduating college, Michael Jaharis purchased his first pharmaceutical company. That was in 1972. Four decades later he had amassed a career — and a fortune — in the pharmaceutical industry highlighted by the sales of three companies: Key Pharmaceuticals, Kos Pharmaceuticals, and Pearl Therapeutics.

  • Japan’s Take On Regenerative Medicine: Early Commercialization, Early Reimbursement
    Japan’s Take On Regenerative Medicine: Early Commercialization, Early Reimbursement

    New regulations accelerating the approval of regenerative therapeutics in Japan took effect Nov. 25, 2014, propelling that nation onto the radar screens of life sciences companies around the world. The chief benefit of these new rules is that they enable companies to receive conditional marketing approval and generate revenue from regenerative products while trials are being conducted.

  • Drug Development In The Age Of Social Media
    Drug Development In The Age Of Social Media

    A young, energetic biotech; a promising drug with encouraging Phase 2 data; a young patient population; a disease target for which there is no successful treatment.

More Magazine Articles....
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

VIEW THE DIGITAL EDITION

CMO SUPPLEMENT: HOW TO SELECT A CMO AND QUALIFY ITS CAPABILITIES

 UPCOMING EVENTS

Communication With FDA: What Do We Say And How Do We Say It?

April 28, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

2015 Canadian Pharma Market Research Conference

April 28 - 29, 2015
Toronto, ON

Clinical Finance: Key Strategies to Stay in Control of Your Study Budget

April 29, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

Qualifying Your Trainers – What Do They Need For Your Training To Be Effective?

May 5, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate
See All Events